AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
Advertisement
AiCuris Anti-infective Cures AG (AiCuris) and Hybridize Therapeutics (Hybridize) announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. The licensed program is based on a novel RNA-based therapeutic approach developed by Hybridize.
Symbolic image
pixabay.com
Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize’s BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients. Hybridize will receive an upfront payment and further milestone payments of up to €100 million in total based on successful achievement of development, regulatory and commercialization goals. In addition, Hybridize will receive tiered royalties on net sales. Hybridize and AiCuris will collaborate in the further development of the BKV-targeting therapy until the start of clinical studies, which is expected within two years.
“We are excited to gain the rights to this exciting RNA-based antisense approach against BKV infections, further strengthening our anti-infective pipeline and building on our strong track record in the field of infectious diseases in transplant patients,” said Dr. Holger Zimmermann, CEO of AiCuris. “With PREVYMIS® approved and licensed to MSD for use in bone marrow transplants for the prevention of cytomegalovirus (CMV) infections, and Pritelivir in phase 3 development for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients, this BKV-targeting RNA-based therapeutic approach represents our third project in the field of transplantation medicine.”
“BKV infection is one of the most common viral infections affecting kidney transplant patients. Yet, there are no treatments approved to fight them,” he continued. “BK virus is difficult to treat as it is not addressable using conventional approaches such as classical enzyme inhibitors. We believe that antisense oligonucleotides are a promising novel approach to block BKV replication. If shown to be safe and effective, this approach could be a true game changer in transplantation medicine with the potential to prevent kidney transplant patients from developing graft rejection and organ loss due to BKV.”
Hybridize’s RNA-based program is designed to target a protein critical for viral replication by modulating the splicing process of the protein-encoding mRNA, preventing its synthesis and thus replication of the virus. The Hybridize program is believed to be the only direct acting antiviral therapeutic in development, working intracellularly and therefore protecting the kidney cells from within. In several scientific papers, antisense oligonucleotides were shown to be effective inhibitors of hepatitis B virus replication in vitro.
“Today’s announcement represents a major milestone and a great validation for our cutting-edge RNA platform technology, and testament to the creative intelligence at the LUMC and great execution of our team to progress this program to this stage,” said Eline van Beest, CEO of Hybridize Therapeutics. “We are convinced that AiCuris’ excellence in the development of anti-infective therapies and its deep and proven experience in bringing drug candidates through clinical development and onto the market makes them the perfect partner to advance our RNA-based BKV program to the clinic. We are very much looking forward to working with the AiCuris team to accelerate the delivery of this promising program to patients who suffer from BKV-associated nephropathy. Also, the upfront and milestone payments will considerably increase our fire power and allow us to expand our proprietary pipeline with a number of as yet undisclosed RNA therapies.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Stora Enso enters into strategic partnership with Swedish University of Agricultural Sciences
Images of NMDA receptors help explain how they are affected by zinc and a drug
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
